Mycenax Biotech Inc. (TPEX:4726)
Taiwan · Delayed Price · Currency is TWD 23.90
+0.20 (0.84%)
Sep 8, 2026, 1:30 PM CST
Mycenax Biotech Market Cap
Mycenax Biotech has a market cap or net worth of 4.95 billion as of September 8, 2026. Its market cap has decreased by -38.90% in one year.
Market Cap
4.95B
Enterprise Value
5.81B
Revenue
815.87M
Ranking
n/a
PE Ratio
n/a
Stock Price
23.90
ChartMarket Cap Chart
Since October 31, 2008, Mycenax Biotech's market cap has increased from 584.10M to 4.95B, an increase of 747.17%. That is a compound annual growth rate of 12.70%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 8, 2026 | 4.95B | -24.42% |
| Dec 31, 2025 | 6.55B | -26.98% |
| Dec 31, 2024 | 8.97B | 22.00% |
| Dec 29, 2023 | 7.35B | -4.53% |
| Dec 30, 2022 | 7.70B | 32.48% |
| Dec 30, 2021 | 5.81B | 40.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| TaiGen Biopharmaceuticals Holdings | 6.53B |
| AnnJi Pharmaceutical | 6.39B |
| Savior Lifetec | 6.28B |
| Sinphar Pharmaceutical | 6.17B |
| Steminent Biotherapeutics | 6.16B |
| Medigen Biotechnology | 4.88B |
| UnicoCell Biomed | 4.76B |
| Pharmosa Biopharm | 4.28B |